CeloNova reports late-breaking evidence from COBRA-REDUCE trial

In the study, 100% of enrolled patients were on oral anticoagulation therapy (OAC), which is a major bleeding criterion with over 90% of patients presenting with atrial fibrillation. Credit: crystal light / Shutterstock.